Evaluation of carcinoembryonic antigen‐related cell adhesion molecule 1 blood serum levels in women at high risk for preeclampsia. (25th November 2020)

• Record Type: Journal Article
• Authors: Mach, Pawel; Andrikos, Dimitrios; Schmidt, Boerge; Gellhaus, Alexandra; Rusch, Peter; Birdir, Cahit; Andrikos, Argyrios; Schmitt, Verena; Kimmig, Rainer; Singer, Bernhard B.; Köninger, Angela
• Is Part Of: American journal of reproductive immunology. Volume 85:Number 5(2021)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2020-11-25
• Subjects: CEACAM1 -- immune tolerance -- preeclampsia; Human reproduction -- Immunological aspects -- Periodicals; 616.69206
• DOI: 10.1111/aji.13375
• Languages: English
• ISSNs: 1046-7408

Abstract

Abstract: Problem: The aim of this study was to evaluate the sCEACAM1 concentrations in serum from patients in the first trimester who have a high risk for developing PE during pregnancy. Method of the study: Carcinoembryonic antigen‐related cell adhesion molecule 1 (CEACAM1) levels were determined with ELISA. The patients ( n = 109) were divided into two groups: patients who have a high risk of developing PE early‐onset and a control group. Patients who have a high risk of developing PE were then divided into two subgroups depending on PE development in third trimester of pregnancy: PE in third trimester versus no PE in third trimester. Results: sCEACAM1 concentrations in patients who were screened as having a high risk for developing PE were significantly higher than in healthy pregnant women in the first trimester ( p = .03). The highest sCEACAM1 concentration was found in the high‐risk group with PE development compared to the control group ( p = .004). Conclusion: Elevated sCEACAM1 blood serum levels in women with PE suggest that there is immune dysregulation in early pregnancy, which may be helpful in PE prediction and therapy.